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ABSTRACT
Despite decades of intense research, the complex biology 
of glioblastoma (GBM) is not completely understood. 
Progression-free survival and overall survival have 
remained unchanged since the implementation of 
the STUPP regimen in 2005 with concomitant radio-/
chemotherapy and adjuvant chemotherapy with 
temozolomide.
In the context of Hanahan and Weinberg's six hallmarks 
and two emerging hallmarks of cancer, we discuss up-to-
date status and recent research in the biology of GBM. We 
discuss the clinical impact of the research results with the 
most promising being in the hallmarks ‘enabling replicative 
immortality’, ‘inducing angiogenesis’, ‘reprogramming 
cellular energetics’ and ‘evading immune destruction’.
This includes the importance of molecular diagnostics 
according to the new WHO classification and how next 
generation sequencing is being implemented in the clinical 
daily life. Molecular results linked together with clinical 
outcome have revealed the importance of the prognostic 
biomarker isocitratedehydrogenase (IDH), which is now part 
of the diagnostic criteria in brain tumours. IDH is discussed 
in the context of the hallmark ‘reprogramming cellular 
energetics’. O-6-methylguanine-DNA methyltransferase 
status predicts a more favourable response to treatment and 
is thus a predictive marker. Based on genomic aberrations, 
Verhaak et al have suggested a division of GBM into three 
subgroups, namely, proneural, classical and mesenchymal, 
which could be meaningful in the clinic and could help 
guide and differentiate treatment decisions according to the 
specific subgroup.
The information achieved, will develop and improve 
precision medicine in the future.
INTRODUCTION
Glioblastoma (GBM) has a complex biology 
and despite decades of research, much is still 
unknown. The incidence is 3.2/100 000,1 and 
GBM is the most malignant brain tumour.
GBM separates from lower grade gliomas 
by expressing necrosis and/or microvascular 
proliferation2 and is characterised by rapid, 
infiltrating growth. GBM can arise either as 
a primary tumour or as a secondary tumour, 
the latter as a malignant transformation from 
a lower grade brain tumour and/or with 
mutation in the isocitrate dehydrogenase 
(IDH) gene.
Treatment in patients with a good perfor-
mance status is multimodal with surgery, 
radiation and chemotherapy. However, in 
spite of the intensive treatment, patients 
have a poor prognosis with a progression-free 
survival (PFS) of 7–8 months, a median 
survival of 14–16 months and 5-year overall 
survival (OS) of 9.8%.3 4
The diagnosis of gliomas has historically 
been by histopathological examination. 
Recent advances have indicated the impor-
tance of molecular subtyping. As such, a 
new WHO classification of GBM into GBM, 
IDH-wildtype, GBM, IDH-mutant and GBM 
not otherwise specified (NOS) was recently 
presented.2 This raises the dilemma of 
contradiction between the histological/
phenotypic diagnosis and the molecular/
genomic diagnosis. The genomic diagnosis 
will then overrule and dictate the diagnosis. 
There has been suggestion of a further subdi-
vision based on the molecular changes by 
Verhaak et al 5 6 and table 1. However, today, 
this subdivision has no role in diagnostics 
and treatment decisions but might help over-
come some of the heterogeneity in GBM and 
improve treatment.
The predictive factor O-6-methylgua-
nine-DNA methyltransferase (MGMT) is now 
used in treatment decisions due to results with 
median OS in patients with MGMT-methyl-
ated tumour of 22–26 months compared with 
non-MGMT-methylated tumours of 12–15 
months, respectively.7
Hanahan and Weinberg8 have made an 
impressive work, investigating the similarities 
in cancer and explaining these from six hall-
marks and two emerging hallmarks. In the 
following below, we discuss these hallmarks in 
the context of GBM.
METHODS
We searched PubMed with no limitation to 
time. Only articles in English were used.
Sustaining proliferative signalling
Normal cell growth is regulated through 
a number of growth signals and paracrine 
signalling that sustains a cell in a healthy, 
normal homeostasis.
Review
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A cancer cell has evolved mechanisms to sustain this 
proliferative signalling by aberrations in the gene signa-
ture. Examples of activating and inactivating mutations 
can be seen in table 2, and a list of the top 20 mutated 
genes in GBM can be seen in figure 1.
The Cancer Genome Atlas (TCGA) group first inves-
tigated the genomic characterisation in GBM in 2008.9 
Two hundred and six specimens of GBM tissue were anal-
ysed, and significant findings were done in the following 
three core pathways: receptor tyrosine kinase (RTK)/
rat sarcoma (RAS)/PI3K, p53 and RB with alterations in 
88%, 78% and 87%, respectively.
The most significant alteration in the RTK/RAS/
PI3K pathway was in epidermal growth factor receptor 
(EGFR) in 45%. EGFR can be altered in a number of 
ways10, and mutation in the EGFR gene results in over-
expression of EGFR in GBM as seen in the classical 
subtype. In total, activating alterations were found in 
70% in the RTKs.
The most significant inactivating alteration was found 
in the PTEN gene in 36%, thereby losing the negative 
feedback to PI3K causing proliferation and decreased 
apoptosis. RAS was only mutated in 2% of the specimens, 
but this is of importance due to the role as a key activator 
and the influence on several proteins downstream.
In the p53 pathway, the most significant findings were 
in 49% of CDKN2A and 35% in TP53.
In the RB pathway, CDKN2A and CDKN2B were inacti-
vated in 52% and 47%, respectively and the gene RB was 
homozygote deleted in 11%.
In 2013, the same specimens were analysed with 
next-generation sequencing (NGS) and another 337 
specimens were added, ending up with 543 tumours.11 
Seventy-one significantly mutated genes (SMGs) were 
found, which many of them corresponded with previous 
findings. In long-term survivors, aberrations in EGFR, 
CDK4 and CDKN2A were less frequent. Focus should 
therefore be on the three pathways described.
Evading growth suppressors
Loss of function in tumour suppressor genes such as NF2, 
LKB1, RB or TP53 is essential. The latter two genes play 
a crucial role in the G1 phase in the cell cycle, having 
the ability to delay entrance into the S-phase to repair the 
damage detected or ultimately cause apoptosis of the cell.
NF2 codes for Merlin which cause binding of cell adhe-
sion molecules such as E-cadherin on the transmembrane 
RTK in the cytoplasm, making the cell adhesion stronger 
and more dense thereby limiting the ability to bind 
growth factors.12 13
Table 2 Examples of oncogenes and tumour suppressor genes
Activating (oncogenes) Inactivating (tumour suppressor genes)
B-RAF Tumour protein (TP53)
Phosphoinositide 3-kinase (PI3K) isoforms Retinoblastoma associated (RB)
Rat sarcoma (RAS) Mammalian target of rapamycin (mTOR)
Epidermal growth factor receptor (EGFR) Phosphatase and tensin homolog (PTEN)
Platelet derived growth factor receptor A (PDGFRA) Breast cancer1 (BRCA1)
Table 1 Subclassification in glioblastoma.
Classical Mutated in EGFR with high expression.
Lacks P53 mutation. CDKN2A deleted which causes inactivation of the RB pathway.
Amplification of chromosome 7 and deletion of chromosome 10.
Classical O-6-methylguanine-DNA methyltransferase (MGMT)-methylated tumours respond 
significantly better to aggressive treatment as compared with non-MGMT-methylated classical 
tumours.
Astrocytic-like.
Mesenchymal Mutated in NF which activates the PI3K/Akt pathway.
Mutated in PTEN which activates the RAS pathway.
Expression of YKL-40 and MET which can cause epithelial-to-mesenchymal transition.
Inflammatory and necrotic. MGMT-methylated mesenchymal tumours seem to respond better to 
aggressive treatment than non-MGMT-methylated tumours, but this is not significant.
Astrocytic-like.
Proneural Mutated in PDGFRA which activates the PI3K pathway and the RAS pathway.
Mutated in P53, IDH and PDGFRA. If PDGFRA is mutated, then IDH will not be mutated and 
opposite.
No difference in response to aggressive treatment when stratified for MGMT status. Often 
secondary glioblastoma.
Oligodendrocytic-like.
Modified and simplified from Verhaak et al,5 Cancer Genome Atlas Research Network,9 Murat et al,32
EGFR, epidermal growth factor; IDH, isocitrate dehydrogenase; RAS, rat sarcoma.
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LKB1 is a key activator of mTOR and acts by altering 
and stabilising the epithelial architecture.14
Mutation in the RB gene is not as common as mutations 
in the protein (p)RB. RB is mutated in most other cancers 
but only 6%–11% in GBM.15 16 PRB acts on extracellular 
signals, and inactivation of pRB can happen in a number 
of ways in the malignant cell; CDK 4 and 6 can phosphor-
ylate pRB, making it inactive and thus allowing the cell 
to enter the G1 phase in the cell cycle or the gene can be 
deleted by mutation. The proteins of the gene CDKN2A 
work by inhibiting CDK4 and 6. When CDKN2A function 
is lost by mutation, this indirectly inhibits the function of 
pRB. It is therefore important to know whether RB insuf-
ficiency is due to RB mutation or due to aberrations in 
the pathway. The latter makes the cancer cell responsive 
to anti-pathway treatment, whereas the first makes it resis-
tant to the same drugs. Studies in breast17 and bladder18 
cancers have shown that loss of pRB makes the cancer 
more susceptible to radiotherapy and chemotherapy, 
suggesting pRB loss as a predictive marker of response 
to such.
The p53 pathway acts on intracellular signals. TP53 is 
mutated in 27%–33.8% of GBM16 19 and is more correlated 
to astrocytomas than to oligodendrogliomas. A total of 
10 isoforms of TP53 have been identified resulting in 
different expression of p5320–22, and it seems that muta-
tions in TP53 are not tumour-type specific but are shared 
across tumour types.23 It also seems that mutations in TP53 
do not change with chemotherapy.24 Other isoforms have 
been identified in patients with breast and ovary cancers 
and acute myeloid leukaemia.20 The different isoforms 
showed different response to treatment and PFS.
This suggests that TP53 may be used as a prognostic 
biomarker in some cancers but not in GBM. In the 
COSMIC-database, the prognostic value has been inves-
tigated. In brain cancer, three studies found a positive 
predictive value, whereas two studies did not and four 
studies were not related to outcome. Only studies with 
more than 50 patients were included.16
The above shows that knowledge is being obtained 
concerning tumour suppressor genes, but it is yet too 
scarce to target these in clinical protocols.
Activating invasion and metastasis
The ability of communication between cancer cells and 
the periphery, the neoplastic stroma, is proving more 
important in terms of invasive growth and metastases.
Since extracranial metastases are extremely rare in 
GBM,25 invasion and migration are the main features of 
GBM spreading.
Three major ways of invasion, migration and metastases 
have been identified, which will be discussed next; the 
collective invasiveness, where the cancer cell invades to 
nearby tissue through existing interstices in the extracel-
lular matrix, thereby expanding from the primary tumour 
but without directly detachment. Connexin 43 (cnx43) 
plays a role in the tight junctions between cells. GBM cells 
can downregulate cnx43, thereby causing lesser adher-
ence and communication between the cells and making 
possible invasion to nearby tissue.26
Another way is invasion by inflammatory cells where 
protumoural immune cells produce extracellular matrix 
degrading enzymes in the periphery, making way for the 
cancer cell and creating an imbalance between tissue 
inhibitor of metalloproteinases and metalloproteinases. 
Hypoxia also causes an increase in proinflammatory 
proteins and cancer stem cells.27 The proinflammatory 
Figure 1 Top 20 mutated genes in glioblastoma based on 712 samples of astrocytoma grade IV.16
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proteins allow for cancer stem cells to differentiate, 
causing gliomagenesis.
Finally, epithelial-to-mesenchymal transition (EMT)28 
can occur. The heterogenous GBM cell can display 
epithelial features, and EMT has been observed in 
GBM.29 For EMT to happen, E-cadherin is often lacking.30 
E-cadherin normally forms junctions between adjacent 
epithelial cells, thereby assisting senescence and dimin-
ishing the ability to grow and invade. When impaired, this 
causes disruption of the normal cell–cell contact and cell 
polarity, enabling cell motility. The cell can then undergo 
epigenetic changes, resulting in dedifferentiation and 
acquisition of stem cell features.
Hypoxia can also recruit myeloid cells. They cause 
upregulation of transforming growth factor (TGF)-β, 
epithelial growth factor, platelet-derived growth factor 
(PDGFRA) and TWIST, which secretes transcription 
factors like N-cadherin that is necessary for EMT. Expres-
sion of TGF-β and TWIST is higher in necrotic areas 
and so is the expression of the stem cell marker CD133. 
Expression of TGF-β in necrotic areas and expression of 
CD133 are correlated to poorer survival.31 32
Enabling replicative immortality
The gene telomerase reverse transcriptase (TERT) causes 
expression of telomerase that can add lengths to the telo-
meres. Telomerase is almost absent in normal cells but is 
abundantly represented in cancer cells, and the gene has 
been found mutated in 51% of GBM.16 This enables the 
cell to avoid telomere shortening and causing an other-
wise doomed cell to reverse into immortality.
In the 2013 TCGA study,11 expression of TERT was 
found in 21/25 cases accessible for investigation. In 
the remaining four samples, mutations were found in 
the transcriptional regulator gene alpha thalassaemia 
mental retardation (ATRX). These alterations were not 
expressed concurrently. They implied that either TERT 
or ATRX is responsible for the telomere lengthening. 
ATRX was expressed concurrently with mutations in TP53 
and IDH1, representing secondary GBM.
Ceccarelli et al  found that ATRX mutation was associ-
ated with lengthening of telomeres while, on the other 
hand, TERT mutated tumours did not have a difference in 
telomere length compared with normal tissue controls.33
To support the latter, the authors of a recently 
published abstract presented at American Society 
of Oncology (ASCO) 2016 investigated 303 patients 
and found human TERT (hTERT) mutation in 75% 
of the patients. In substratification based on hTERT 
status and MGMT methylation, patients with hTERT 
mutation lived significantly longer with median OS of 
28.3 months in methylated tumours and 15.9 months 
in non-MGMT-methylated tumours. No difference 
was observed with hTERT non-mutation regardless 
of MGMT methylation. This was validated in a TCGA 
cohort.34 Whether this means that TERT plays a role in 
the better prognosis in MGMT-methylated tumours, is 
yet to be fully discovered.
Inducing angiogenesis
Vascular endothelial growth factor (VEGF) A gene stim-
ulates angiogenesis and is rather constant. Angiogenesis 
can be stimulated in a variety of ways, for example, by onco-
genes such as RAS and MYC or by inflammatory reactions. 
Bone marrow–derived cells (BMDCs) such as macro-
phages, neutrophils, mast cells and myeloid progenitors 
are recruited due to the peritumoural oedema. Some 
of the recruited vascular progenitor cells can transform 
into pericytes or endothelial cells, protecting and stabi-
lising the newly formed vessel.35 Bevacizumab (BEV) is a 
humanised monoclonal antibody that targets the vascular 
endothelial growth factor receptor.36 It can only cross the 
blood–brain barrier (BBB) where this is destroyed, as 
seen in GBM. BEV was approved in 2009 by the Food and 
Drug Administration (FDA) for treatment of recurrent 
GBM.
A meta-analysis,37 including two large phase III studies, 
the AvaGlio38 and the RTOG085,39 have demonstrated an 
increase in PFS but no influence on OS in newly diag-
nosed GBM patients treated with BEV.
Mechanisms of resistance to BEV are partly due to 
immunogenic disturbances. The BEV-induced hypoxia 
recruits proangiogenic BMDCs, mainly tumour-associ-
ated macrophages,40 thereby ignoring the effect of BEV.
Hypoxia and BMDCs can enable EMT, as 
mentioned above, causing a transformation to the more 
infiltratory mesenchymal subtype.41 Urup et al  investigated 
whether proneural and mesenchymal subtype showed 
predictiveness towards response to BEV and found that 
this was not the case. They found that low gene expres-
sion of angiotensinogen and high expression of human 
leucocyte antigen (HLA) class II were predictive markers 
of response to BEV,42 but this needs to be validated.
Resisting cell death
There are three mechanisms of cell death: apoptosis, 
autophagy and death by necrosis. The mechanisms are 
listed hierarchically.
In a normal cell, apoptosis can be divided into 
an extrinsic part (death receptor mediated) and an 
intrinsic part (mitochondria-mediated) (figure 2). Aber-
rations in these subtle mechanisms can lead to avoidance 
of apoptosis, which can also be achieved by loss of TP53 
and RB. PI3K, AKT and mTOR can block apoptosis and 
autophagy when survival signals are abundant.
Another aspect is autophagy, which happens with 
metabolic stress, nutrient limitation or dysfunction of 
organelles, thereby decreasing the activity of the cell. 
The metabolites produced can be used as energy, also 
in a cancer cell where energy is sparse. This represents 
a dilemma as autophagy in the early stage cancer can 
be tumour degrading and in late-stage cancer, can be 
tumour enhancing.
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Cell death by necrosis mediates a proinflammatory 
response in the microenvironment. This activates the 
adaptive immune response with recruitment of BMDCs. 
Therefore, cell death by necrosis is considered as collateral 
damage for a tumour cell. Hence, if autophagy is impaired 
together with a defective apoptosis, a cell can become 
tumourigenic or die by necrosis and inflammation, causing 
even more space for tumourigenesis and a poor prognosis.43
In GBM, it seems that the cells are more prone to death 
by necrosis or autophagy as they are in a large extent 
resistant to death by apoptosis due to impairment of TP53 
or RB.44 45 As an example, temozolomide induces death 
by autophagy.46 Selective autophagy may be a potential 
target, and the importance of autophagy was highlighted 
by the recognition of 2016 Nobel Prize winner in medi-
cine, cell biologist Yoshinori Ohsumi.47
In a study of 350 specimens of astrocytomas WHO 
grades I–IV, it was found that autophagy is enhanced in 
astrocytomas regardless of WHO grade and prognosis, 
casting light once again on the microenvironment.48
Evading immune destruction
The immune system is constantly surveilling the homeo-
stasis and an immune competent person is able to 
eradicate many cancers in the making.49 Experiments in 
immune incompetent mice where cytotoxic T-lympho-
cytes (CTLs) and natural killer cells were depleted showed 
an increasing tendency towards developing cancer.50
GBM cells are able to avoid an immune response due 
to a limited number of antigens and an ability to recruit 
myeloid-derived suppressor cells. However, GBM causes 
leaks in the astrocytic end feet that are part of the BBB.51
Presently, the main focus is on peptide and dendritic 
cell vaccines and checkpoint inhibitors.
Rindopepimut is an EGFRvIII peptide vaccine conju-
gated to an immunogenic carrier protein and admixed 
with the adjuvant granulocyte macrophage colony-stim-
ulating factor.52 Rindopepimut was investigated in the 
phase II trial ReACT for patients with relapse of GBM.53 
They were randomised to BEV plus Rindopepimut or 
control. Preliminary results presented at ASCO 2015 
showed a significant OS of 11.3 months in the Rindo-
pepimut group compared with 9.3 in the control group 
and an objective response rate of 23%–30% vs 9%–18%, 
respectively. In the single arm phase II trial, ACT III, for 
patients with newly diagnosed GBM, a median PFS and 
OS of 9.2 and 21.8 months were found, respectively. The 
results were better for patients with MGMT methyla-
tion.54 A double-blind phase III trial, the ACT IV was then 
initiated. However, the protocol has been stopped, since 
it was found that the study would not meet its primary 
OS endpoint. Noteworthy was that the control group 
Figure 2 The intrinsic apoptotic pathway is a balance between proapoptotic proteins, for example, Bax and Bak and 
antiapoptotic proteins. The latter works by inhibiting Bax and Bak. When the inhibition stops, Bax and Bak change the 
mitochondrial outer membrane, causing release of cytochrome C, which triggers the Caspases and causes apoptosis.87
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lived longer than predicted based on historical-matched 
control groups and thus might have masked the effect of 
Rindopepimut. Patients treated with the drug prior to 
termination of the protocol are still offered treatment in 
compassionate use programmes.55
Another study investigating actively personalised 
peptide vaccination (GAPVAC) is being performed 
in newly diagnosed patients and is now closed for 
 inclusion.56
A dendritic cell vaccine works by acting as an anti-
gen-presenting cell. It is possible either to extract 
autologous antigen-specific T cells, expand them ex 
vivo and re-infuse into patients or by vaccination with an 
antigen together with an adjuvant.57
A phase I/II trial including 22 patients with grade 
II–IV gliomas, showed a positive immunological response 
in 13 patients.58 The procedure, though, is time consuming 
and it seems that only 4% of the injected vaccine arrive 
at the draining lymph node.59 Other studies have shown 
increased effect by prestimulation of the injection site.60
CTL-4 and programmed death 1 (PD1) are receptors 
on the T-cell causing apoptosis of the T-cell when abun-
dant and inappropriate, thereby preventing development 
of autoimmune diseases. Cancer cells can bind to these 
receptors, causing apoptosis of the T-cell. A CTL-4 inhib-
itor revolutionised the treatment of unresectable 
malignant melanoma when Ipilimumab was approved by 
FDA in 2011.61
A PD1 inhibitor is a monoclonal antibody that binds 
to and occupies the PD1 receptor. PD1 inhibitors are 
now being investigated in first-line settings of GBM.62 63 
A combination with CTL-4 and PD1 inhibitors are also 
being performed and immune checkpoint inhibitors 
could potentially be more effective with prepriming of 
the immune system with a dendritic cell vaccine or a 
peptide vaccine.64
Another promising field of research is in the oncolytic 
viro therapy where poliovirus is genetically engineered 
with rhinovirus (PVSRIPO). PVSRIPO binds to the Ig 
superfamily adhesion molecule CD155 or Necl5, which 
GBM cells express.65 The effect is local and cytotoxic.66 A 
trial with 22 GBM patients with relapse is being performed 
at Preston Robert Tisch Brain Tumor Center at Duke 
University, USA. The treatment is promising and phase 
II/III trials are being planned.
Autologous lymphoid effector cells specific against 
tumour cells (ALECSAT) in recurrent GBM have also 
been tested. No increase in PFS or OS was found, and the 
study was stopped prematurely.67 It has been suggested 
that the negative results could be explained due to the 
fact that patients in the ALECSAT group started treat-
ment 28 days after standard treatment with BEV and 
Irinotecan in the control group68 and different set-up may 
be investigated.
Reprogramming cellular energetics
Cancer cells can reprogram their metabolism into 
favouring anaerob glycolysis followed by lactate acid 
fermentation in the cytosol,69 thereby producing only 
two-three molecules of ATP per molecule glucose instead 
of the 38 accomplished through mitochondrial oxidative 
phosphorylation. This is overcome by upregulating the 
number of glucose uptake receptors, namely GLUT1, a 
trade achieved by RAS, MYC and TP53. The anaerobic 
glycolysis produces intermediates used to facilitate other 
biosynthetic pathways.
Five metabolic IDH genes have been defined, coding 
for three IDH enzymes. The enzymes are responsible 
for the oxidative carboxylation of isocitrate to α-keto-
glutarate producing nicotinamide adenine dinucleotide 
phosphate (NADPH).
IDH1 is localised in the cytosol and peroxisome, deliv-
ering energy to production of peroxisomal enzymes 
thereby affecting many metabolic pathways. IDH2 and 
IDH3 are localised in the mitochondria, functioning in 
the tricarboxylic acid cycle, supporting cell growth.70
Only IDH1 and IDH2 are found mutated in GBM; they 
exert the same mutagenic effect71 and are settled prog-
nostic markers for lower grade gliomas and secondary 
GBM.72 IDH is found mutated in 70% of lower grade 
gliomas and secondary GBM and up to 5% in primary 
GBM.71
IDH mutations decrease the normal IDH activity by 
approximately 50%, thereby producing less α-ketogluta-
rate and NADPH and instead produce the onco-metabolite 
2-hydroxyglutarate (2-HG) using NADPH, which lowers 
NADPH further.73 2-HG is an inhibitor of α-ketogluta-
rate-dependent dioxygenases, which may cause epigenetic 
changes, including hypermethylation in human gliomas.74 
It can also induce an increased removal of an insulator 
protein, which enables increased contact to PDGFRA, 
thereby further inducing gliomagenesis.75
With the impaired function of the mitochondria, the 
production of bioenergy and intermediates is decreased 
hence the growth of the cancer cell is lowered when 
compared with IDH-WT gliomas.76 Preliminary data 
suggest that inhibition of glutaminase which is necessary 
for production of 2-HG cause slow-down of glioma cell 
growth77 78, but the data are still immature for therapeutic 
use.
Studies are emerging though, with the purpose to target 
IDH mutations. Hence, preliminary data for the AG12079 
trial in the glioma expansion cohort with recurrence or 
progression of GBM showed a response in 2% and stable 
disease in 83%. (Mellinghoff IK et al Abstract ACTR-46, 
SNO 2016). A phase I study AG881 with a pan inhibitor 
of IDH80 is being evaluated, and another phase I study, 
the NOA16, is investigating treatment in grade III and 
IV gliomas with an IDH1 peptide vaccine targeting the 
IDH1R132H.81
In a study of 105 specimens of GBM, 12% had muta-
tions in IDH1 and in these, 83% had mutations in TP53 as 
opposed to only 27% in the IDH1-WT tumours. None of 
the IDH1 mutated tumours had mutations in PTEN, RB1, 
EGFR or NF1 as opposed to 60% in IDH1-WT tumours. 
The IDH mutated patients had more favourably clinical 
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features regarding median age at diagnosis, frequency of 
recurrent GBM, secondary GBM and median OS.82
In a meta-analysis including 24 studies with GBM and 
IDH1 and −2 status, it was found that IDH mutations were 
prognostic factors for a better OS and PFS. A total of 15 
studies included data for OS. The HR was 0.36 (95% CI 
0.26 to 0.49, p<0.001) favouring IDH mutations. Out of 
the 15 studies, eight included data for PFS, and the HR 
was 0.32 (95% CI 0.24 to 0.46, p<0.001) favouring IDH 
mutations.83
IDH mutations have been identified in a number of 
other cancer types with the highest frequency in GBM 
and melanoma.84–86
CONCLUSION AND PERSPECTIVES
The most promising next steps are in the hallmarks 
‘enabling replicative immortality’, ‘inducing angiogen-
esis’, ‘reprogramming cellular energetics’ and ‘evading 
immune destruction’ where the challenge is not to find 
differences but to find similarities in GBM. The hallmark 
with the greatest clinical impact is in ‘evading immune 
destruction’, where immune therapy might actually repre-
sent a similarity in cancer treatment. Promising results 
have been achieved both in first-line and second-line 
settings, and development of clinical trials with combina-
tion therapy with different immunogenic therapies and/
or radiotherapy together with predictive markers might 
improve results even further. Defining and developing 
prognostic and predictive markers for better patient selec-
tion and treatment response is important. Such could be 
TERT mutation combined with MGMT methylation, which 
have showed improved OS or high HLA and low angioten-
sinogen for treatment response with BEV. Development of 
liquid biopsies for these markers will increase the clinical 
usability. The metabolism of GBM is another promising 
field with the role of IDH which represents epigenetic 
changes and thus a possibility to target the trunk of GBM 
instead of the branches where the complexity increases.
More individual treatment is warranted. This is 
becoming even more evident with the new WHO classifi-
cation. Research in the three subclasses also represents the 
molecular focus. The SMGs identified in each subclass has 
significance in each of the six hallmarks and two emerging 
hallmarks. Different responses to aggressive treatment 
together with stratification for MGMT status in each subclass 
have been demonstrated. This indicates that a patient with, 
for example, subclass proneural, MGMT non-methylated, 
perhaps should not be offered STUPP regimen, but rather 
another 1st line treatment and one might hypothesise that 
a patient with a mesenchymal tumour and hence more 
inflammation and death by necrosis might respond better 
to immune therapy. All this needs further validation but is 
a clinical meaningful way of thinking.
NGS is expanding, and the handling of and inter-
pretation of big data from these analyses should be 
carefully evaluated and validated. NGS may provide a 
more detailed information on GBM to help overcome 
some of the heterogeneity that challenges today's treat-
ment, as today's treatment is not differentiated according 
to, for example, molecular aberrations except IDH status 
and MGMT methylation status. This will have increased 
importance in the future.
With the economical accessibility, more laboratories 
will be performing NGS with different equipment and 
experience. Therefore, development of quality assess-
ments and reproducibility is important, and NGS should 
only be performed in laboratories with the necessary 
requirements for this. The challenge is well illustrated by 
tests for MGMT methylation where this can be performed 
either by immunohistochemistry or PCR. The latter is 
considered the most reproducible and independent of 
interobserver variability, and the first is the most acces-
sible for the community but still there is not consensus 
on this field.
International cooperation with data sharing is neces-
sary in order to enter the era of precision medicine.
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